Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Largest Insider Buys in Sector
CTNM Stock Price History Chart
CTNM Stock Performance
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type …
Insider Activity of Contineum Therapeutics, Inc. Class A Common Stock
Over the last 12 months, insiders at Contineum Therapeutics, Inc. Class A Common Stock have bought $0 and sold $117,598 worth of Contineum Therapeutics, Inc. Class A Common Stock stock.
On average, over the past 5 years, insiders at Contineum Therapeutics, Inc. Class A Common Stock have bought $0 and sold $117,598 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Contineum Therapeutics, Inc. Class A Common Stock
| 2024-11-25 | Sale | Chief Scientific Officer | 1,010 0.0042% | $16.02 | $16,177 | -7.23% | ||
| 2024-11-18 | Sale | Chief Scientific Officer | 6,190 0.0264% | $16.38 | $101,421 | -9.98% |